^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Phase III BOSTON Study Finds Selinexor Improves Outcomes in Myeloma

Published date:
07/10/2020
Excerpt:
Selinexor/bortezomib/dexamethasone significantly prolonged median progression-free survival compared with the doublet: 13.93 months vs 9.46 months (hazard ratio [HR] = 0.70; P = .0075). This was true for all subgroups, including patients with 17p deletions and those previously treated with lenalidomide.
Secondary therapy:
dexamethasone
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Excerpt:
The RP2D is selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle....Two of the 4 patients with documented high-risk cytogenetics at screening responded to therapy, including 1 CR t(4;14) and 1 VGPR del(17p), and were maintained on study for 17.8 and 23.0+ months, respectively...
Secondary therapy:
dexamethasone
DOI:
https://dx.doi.org/10.1182%2Fblood-2018-06-858852
Trial ID: